YN290128 FT895 2225728-57-2

FT895 is a potent and selectiveHDAC11inhibitor with an IC50 of 3nM.

YN340124 FM-479 2226521-64-6

FM-479 is thenegative controlof FM-381 (HY-102046) and has no activity on JAK3 or other kinases. FM-381 is a potent covalent reversible inhibitor ofJAK3targeting the unique Cys909. FM-381 has an IC50 of 127 pM for JA...

YN340032 FM-381 2226521-65-7

FM-381 is a potent covalent reversible inhibitor ofJAK3targeting the unique Cys909. FM-381 has an IC50 of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK2, respectively.

YN310121 ZL0420 2230496-80-5

ZL0420 is a potent and selective bromodomain-containing protein 4 (BRD4) inhibitor with IC50 values of 27nM against BRD4 BD1 and 32nM against BRD4 BD2.

YN430093 MT-802 2231744-29-7

MT-802 is a potentBTKdegrader based onPROTACtechnology, with aDC50of 1nM. MT-802 has potential to treat C481S mutant chronic lymphocytic leukemia (CLL).

YN410033 Keap1-Nrf2-IN-1 2232112-72-8

Keap1-Nrf2-IN-1 (compound35) is aKelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (Keap1-Nrf2) protein-protein interactioninhibitor, and with an IC50 of 43nM for Keap1 protein. Keap1-Nrf2-IN...

YN1710018 AB928 2239273-34-6

AB928 is an orally bioavailable, selective dual adenosine receptor(A2aR/A2bR)antagonist. AB928 relieves adenosine-mediated immune suppression. AB928 has immunomodulatory and antitumor activities.

YN340110 AS2863619 free base 2241300-50-3

AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3+regulatory T (Treg) cells for the treatment of various immunological diseases. AS2863619 free base is a potent, orally activecyclin-depend...

YN340111 AS2863619 2241300-51-4

AS2863619 is a small-molecule cyclin-dependent kinase CDK8/19 inhibitor with IC50 of 0.6099 nM and 4.277 nM, respectively. AS2863619 is a potent Foxp3 inducer in T_{conv cells.}

YN480554 SMS2-IN-2 2241838-28-6

SMS2-IN-2 is a potent, highly selective and orally activesphingomyelin synthase 2 (SMS2)inhibitor, with IC50s of 100nM and 56μM for SMS2 and SMS1, respectively. Anti-chronic inflammatory activity.

YN330220 MD2-TLR4-IN-1 2249801-12-3

MD2-TLR4-IN-1 (compound 22m) is an inhibitor of myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex, inhibiting lipopolysaccharides (LPS)-induced expression of tumor necrosis factor alpha (TNF-α) an...

YN483584 N-Hydroxypipecolic acid pota... 2253632-01-6

N-Hydroxypipecolic acid potassium (1-Hydroxy-2-piperidinecarboxylic acid potassium), a plant metabolite and a systemic acquired resistance (SAR) regulator, orchestrates SAR establishment in concert with the immune signal salicyli...

YN350074 LUT014 2274819-46-2

LUT014 is aB-Rafinhibitor with an IC50 of 11.7nM, and developed to reduce dose-limiting acneiform lesions associated EGFR Inhibitors treatment. Extracted from patent WO 2019026065A2.

YN270205 MYCi975 2289691-01-4

MYCi975 is a potent, selective and orally active inhibitor of MYC that disrupts MYC/MAX interaction, promotes MYC T58 phosphorylation and MYC degradation, and impairs MYC driven gene expression. MYCi975 exhibits pot...

YN480827 TH5487 2304947-71-3

TH5487 is a selective active-site inhibitor of 8-oxoguanine DNA glycosylase 1 (OGG1) with IC50 of 342 nM.

YN371641 PDK4-IN-1 hydrochloride 2310262-11-2

PDK4-IN-1 hydrochloride is an anthraquinone derivative and a potent and orally activepyruvate dehydrogenase kinase 4 (PDK4)inhibitor with an IC50 value of 84nM. PDK4-IN-1 hydrochloride potently represses cellular transfo...

YN320623 S1PR1 modulator 1 2328109-05-1

S1PR1 modulator 1 is a selectiveS1PR1inhibitor, with apIC50 of 7.6, with >40- and >80-fold selectivity, over the other S1PR isoforms S1PR2/3/4.

YN430212 (S,R,S)-AHPC-C8-NH2 2341796-79-8

(S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) is a synthesizedE3 ligase lig and -linker conjugatethat incorporates the VH032 based VHL lig and and a linker used forAKTPROTAC degrader. (S,R,S)-AHPC-C8-NH2 is X...

YN480618 NVS-ZP7-4 2349367-89-9

NVS-ZP7-4 is a Zinc transporter SLC39A7(ZIP7)inhibitor that is also the first reported chemical tool to probe the impact of modulating ER zinc levels and investigate ZIP7 as a novel druggable node in the Notch pathway.

YN480914 SPL-410 2351886-00-3

SPL-410 is an orally active, highly potent and selective hydroxyethylamine basedSPPL2a (Signal Peptide Peptidase Like 2a)inhibitor, with an IC50 of 9nM.